B.A. Van Krimpen

581 total citations
15 papers, 471 citations indexed

About

B.A. Van Krimpen is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, B.A. Van Krimpen has authored 15 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 12 papers in Oncology and 4 papers in Genetics. Recurrent topics in B.A. Van Krimpen's work include CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (9 papers) and Immunotherapy and Immune Responses (5 papers). B.A. Van Krimpen is often cited by papers focused on CAR-T cell therapy research (10 papers), Immune Cell Function and Interaction (9 papers) and Immunotherapy and Immune Responses (5 papers). B.A. Van Krimpen collaborates with scholars based in Netherlands, North Macedonia and United States. B.A. Van Krimpen's co-authors include R. L. H. Bolhuis, R J van de Griend, C. P. M. Ronteltap, Eric Braakman, S. J. L. Bol, Angus Thompson, R. L. H. Bolhuis, Ralph A. Willemsen, M. J. Giphart and Jan G. J. van de Winkel and has published in prestigious journals such as The Journal of Immunology, International Journal of Cancer and European Journal of Immunology.

In The Last Decade

B.A. Van Krimpen

15 papers receiving 452 citations

Peers

Countries citing papers authored by B.A. Van Krimpen

Since Specialization

Citations

This map shows the geographic impact of B.A. Van Krimpen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B.A. Van Krimpen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B.A. Van Krimpen more than expected).

Fields of papers citing papers by B.A. Van Krimpen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B.A. Van Krimpen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B.A. Van Krimpen. The network helps show where B.A. Van Krimpen may publish in the future.

Co-authorship network of co-authors of B.A. Van Krimpen

This figure shows the co-authorship network connecting the top 25 collaborators of B.A. Van Krimpen. A scholar is included among the top collaborators of B.A. Van Krimpen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B.A. Van Krimpen. B.A. Van Krimpen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells 2013 ·Cytotherapy ·C. B. H. W. Lamers, (unknown), (unknown), (unknown), C.A.M. van der Velden-de Groot, B.A. Van Krimpen, Arnold G. Vulto, Stefan Sleijfer, Reno Debets, Jan W. Gratama	4
2	Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer 2005 ·Cancer Gene Therapy ·C. B. H. W. Lamers, Ralph A. Willemsen, (unknown), B.A. Van Krimpen, Jan W. Gratama, Reno Debets	31
3	Parallel Detection of Transduced T Lymphocytes After Immunogene Therapy of Renal Cell Cancer by Flow Cytometry and Real-Time Polymerase Chain Reaction: Implications for Loss of Transgene Expression 2005 ·Human Gene Therapy ·C. B. H. W. Lamers, J.W. Gratama, Nadine Pouw, (unknown), B.A. Van Krimpen, Jaco Kraan, G. Stoter, Reno Debets	35
4	Parallel Detection of Transduced T Lymphocytes After Immunogene Therapy of Renal Cell Cancer by Flow Cytometry and Real-Time Polymerase Chain Reaction: Implications for Loss of Transgene Expression 2005 ·Human Gene Therapy ·(unknown), (unknown), (unknown), (unknown), B.A. Van Krimpen, (unknown), (unknown), (unknown)	1
5	Chimeric scFv/γ receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules 1998 ·International Journal of Cancer ·M. E. M. Weijtens, Ralph A. Willemsen, B.A. Van Krimpen, R. L. H. Bolhuis	36
6	CD16 on human γδ T lymphocytes: Expression, function, and specificity for mouse IgG isotypes 1992 ·Cellular Immunology ·Eric Braakman, Jan G. J. van de Winkel, B.A. Van Krimpen, Margriet Jansze, R. L. H. Bolhuis	62
7	Genetic correction of cultured T cells from an adenosine deaminase‐deficient patient: Characteristics of non‐transduced and transduced T cells 1992 ·European Journal of Immunology ·Eric Braakman, Victor W. van Beusechem, B.A. Van Krimpen, Alain Fischer, R. L. H. Bolhuis, Dinko Valerio	12
8	Expression of CD45 isoforms by fresh and activated human γδ T lymphocytes and natural killer cells 1991 ·International Immunology ·Eric Braakman, Els Sturm, Kitty Vijverberg, B.A. Van Krimpen, Jan W. Gratama, R. L. H. Bolhuis, Lorenzo Moretta	32
9	Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/CD3+ lymphocytes. 1989 ·The Journal of Immunology ·P.J. Voogt, J.H. Frederik Falkenburg, W.E. Fibbe, W. F. J. Veenhof, Mary Jo Hamilton, B.A. Van Krimpen, R. L. H. Bolhuis	8
10	Induction of lysis by T cell receptor gamma delta+/CD3+ T lymphocytes via CD2 requires triggering via the T11.1 epitope only. 1989 ·The Journal of Immunology ·P S Goedegebuure, David M. Segal, E Braakman, (unknown), B.A. Van Krimpen, R J van de Griend, (unknown)	17
11	Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta. 1987 ·The Journal of Immunology ·R J van de Griend, W.J.M. Tax, B.A. Van Krimpen, (unknown), C. P. M. Ronteltap, R. L. H. Bolhuis	57
12	Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non-gamma, or null cells. 1984 ·The Journal of Immunology ·R J van de Griend, B.A. Van Krimpen, C. P. M. Ronteltap, R. L. H. Bolhuis	53
13	Rapid expansion of human cytotoxic T cell clones: Growth promotion by a heat-labile serum component and by various types of feeder cells 1984 ·Journal of Immunological Methods ·R J van de Griend, B.A. Van Krimpen, S. J. L. Bol, Angus Thompson, R. L. H. Bolhuis	69
14	Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies. 1984 ·The Journal of Immunology ·R J van de Griend, M. J. Giphart, B.A. Van Krimpen, R. L. H. Bolhuis	46
15	Phytohaemagglutinin-induced susceptibility to lysis by natural and activated killer cells of autologous allogeneic and xenogeneic target cells 1982 ·Molecular Immunology ·R. L. H. Bolhuis, C. P. M. Ronteltap, (unknown), B.A. Van Krimpen, Huub Schellekens	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact